Advances in Vyxeos Therapy Research with Jeffrey Lancet, MD

Dr. Jeffrey Lancet, Leukemia expert and Department Chair of Malignant Hematology at Moffitt Cancer Center, speaks with HealthTree about his department's ongoing research related to daunorubicin and cytarabine (Vyxeos, Jazz Pharmaceuticals). 

He highlights the importance of identifying molecular predictors of response to Vyxeos so that treatment can be fine-tuned based on each patient's unique genetic and biological features. Additionally, he talks about the significance of understanding the depth of remission that Vyxeos can induce and the ability to combine this therapy with other targeted therapies to yield positive results. Dr. Lancet also mentions the clinical trials that they are running at Moffitt to combine Vyxeos with additional drugs, such as an FLT3 inhibitor and an anti-CD33 antibody-drug conjugate, with hopes of improving outcomes for patients.

Exploring New Possibilities in AML Treatment: Understanding Vyxeos and Beyond

At Moffitt Cancer Center, they are working on different aspects related to Vyxeos, a treatment for acute myeloid leukemia (AML), trying to better understand how certain genetic factors may influence how well Vyxeos works for different patients. By learning more about this, they hope to offer more personalized treatments based on each patient's unique genetic and biological makeup.

They are also looking into how well Vyxeos can help patients achieve a deep remission, which is important for a better long-term outcome. This could give a better idea of which patients might benefit from further treatments like a transplant.

Importantly, they are also exploring the potential of combining Vyxeos with other targeted therapies. Combining Vyxeos with other treatments may lead to better results for patients. Some ongoing clinical trials are investigating the combination of Vyxeos with other drugs like gilteritinib (Xospata, Astellas) and gemtuzumab ozogamicin (Myleotarg, Pfizer). These combinations could potentially improve outcomes compared to using these treatments alone.

Open Clinical Trials

For more information about one of the clinical trials Dr. Lancet mentions in the video above, visit the trial's listing on HealthTree's Clinical Trial Finder:

Vyexos in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML